Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAggressive LymphomasIndolent LymphomasTransplantationDiseaseChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaHodgkin LymphomaMantle Cell LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, Lymphoplasmocytic / Waldenström's diseaseNHL, B-Cell Type, Marginal Zone LymphomaStem Cell Transplantation, AllogeneicStem Cell Transplantation, AutologousSubgroupICD10C81.-C82.-C82.7C82.9C83.0C83.1C83.3C88.0-C91.1-Z94.80MeSHHematopoietic Stem Cell TransplantationHodgkin DiseaseLeukemia, Lymphocytic, Chronic, B-CellLymphoma, FollicularTransplantation, AutologousTransplantation ConditioningSequenceChemotherapyChemo-substanceCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabChemo-substanceCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabChemo-substanceCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabChemo-substanceCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabNo. Substances6 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleCyclophosphamideCytarabineDexamethasoneDimetindenEtoposideFluconazoleFludarabineFosaprepitantFurosemideGranisetronMelphalanMesnaParacetamolPegfilgrastimPrednisoloneRituximabThiotepaUrsodeoxycholic acidValaciclovirSupportive substanceBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleCyclophosphamideCytarabineDexamethasoneDimetindenEtoposideFluconazoleFludarabineFosaprepitantFurosemideGranisetronMelphalanMesnaParacetamolPegfilgrastimPrednisoloneRituximabThiotepaUrsodeoxycholic acidValaciclovirSupportive substanceBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleCyclophosphamideCytarabineDexamethasoneDimetindenEtoposideFluconazoleFludarabineFosaprepitantFurosemideGranisetronMelphalanMesnaParacetamolPegfilgrastimPrednisoloneRituximabThiotepaUrsodeoxycholic acidValaciclovirSupportive substanceBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleCyclophosphamideCytarabineDexamethasoneDimetindenEtoposideFluconazoleFludarabineFosaprepitantFurosemideGranisetronMelphalanMesnaParacetamolPegfilgrastimPrednisoloneRituximabThiotepaUrsodeoxycholic acidValaciclovirNo. Substances61117Protocol classificationTherapy classificationalternativecurrent standardIntensityHochdosis, bei autologer SZTKonditionierung, nicht-myeloablativ (NMA)Standard doseTherapy indicationRelapse therapyseveral possibleTherapy phaseallogene Stammzelltransplantationautologous stem cell transplantationSalvageTherapy intentioncurativeRisksDiarrheaEmetogenicity (MASCC/ESMO)Febrile NeutropeniaMucositis only studiesPublicationAuthorKhouri IFKirschey SLadetto MDiseaseCLL, FL Grad I-IIIa, vor allogener SZTNHL oder HL, auto-SZTrezidivierte aggressive B-NHL, 18-65 Jahre, ECOG 0-2OriginDepartment of Haematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University MainzDepartment of Translational Medicine, University of Eastern Piedmont, Novara, ItalyUniversity of Texas M. D. Anderson Cancer Center, Houston, USAProtokolle in Überarbeitung 3 protocols foundR-DexaBEAM - Rituximab 375 / Dexamethasone 8 / Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 20, B-Non-Hodgkin Lymphoma (PID1006 V1.0)Rituximab 375 / Fludarabine 30 / Cyclophosphamide 750, follicular lymphoma, stages I–IIIa, Allogeneic Stem Cell Transplantation, NMA (PID3223 V1.0)Revision: TEAM - Thiotepa 5 / Etoposide 100 / Cytarabine 200 / Melphalan 140, Autologous Stem Cell Transplantation (PID406 V2.1)
